Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 8/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22677099 | 0.75 | RIPK1 (0.37) | GABRA5 | |
| SCHEMBL22676016 | 0.62 | ACVRL1 (0.43) | — | |
| SCHEMBL25639720 | 0.61 | RIPK1 (0.38) | — | |
| SCHEMBL21198695 | 0.58 | OGG1 (0.55) | — | |
| SCHEMBL13483863 | 0.57 | RAB9A (0.57) | — | |
| SCHEMBL1312068 | 0.57 | ALDH1A1 (0.52) | — | |
| SCHEMBL23116863 | 0.57 | GFER (0.53) | — | |
| SCHEMBL28502010 | 0.57 | NPC1 (0.44) | — | |
| SCHEMBL31641468 | 0.56 | JAK2 (0.44) | — | |
| SCHEMBL5119130 | 0.56 | KDM4E (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | FGFR3, FGFR2, FGFR1 | GABRA5 2378/4885TACR1 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.